Insights derived from analysing SEC filings. Independent analysis, not a publication of the SEC.
Figures are read from the filings of BellRing Brands, Inc. (central index key 1772016): the Q4 and FY2026 results release, supplemental presentation and CFO transition release (8-K Ex 99.1, 99.2 and 99.3 of 18 Nov 2026), the Form 10-K for FY2026 filed the same day, the Forms 10-Q for Q1 to Q3 FY2026, the Forms 10-K for FY2023 to FY2025, the Forms 8-K with all their exhibits, incl. the quarterly results releases with every guidance revision, the CEO appointment, the workforce realignment and the Item 5.07 vote results, Schedules 13G, Forms 4, and the filings of the peers in chapters 2 to 5. BellRing files no separate CFO commentary; CFO and CEO statements come from the 8-K exhibits. Earnings call statements are not used. Category and consumption data are the market data BellRing reports in its 8-K Ex 99.2. Share price $13.66 is the regular session close of 18 Nov 2026, the day of the release. Accession numbers appear in the Sources appendix.
| Line | Q4 FY2025 | Q4 FY2026 | Q4 growth | FY2025 | FY2026 | FY2026 growth |
|---|---|---|---|---|---|---|
| RTD shakes and other beverages | 528.3 | 568.8 | +7.7% | 1,893.6 | 1,943.2 | +2.6% |
| Powders | 104.9 | 108.2 | +3.1% | 366.5 | 393.1 | +7.3% |
| Other products | 15.0 | 15.0 | +0.0% | 56.5 | 62.1 | +9.9% |
| Net sales | 648.2 | 692.0 | +6.8% | 2,316.6 | 2,398.4 | +3.5% |
| Brand: Premier Protein | +7.1% | 1,990.2 | 2,036.0 | +2.3% | ||
| Brand: Dymatize | +3.6% | 279.8 | 309.8 | +10.7% | ||
| Brand: Other brands | 46.6 | 52.6 | +12.9% |
| Metric | FY2025 | FY2026 |
|---|---|---|
| Marketing and consumer advertising ($m) | 75.2 | 91.2 |
| Top three customers, share of net sales (%) | 74.0 | 73.6 |
| Largest customer, share of net sales (%) | 34.3 | 35.3 |
| International, share of net sales (%) | 11.9 | 13.1 |
| Largest contract manufacturer, share of Premier RTD supply (%) | n/a | 42.3 |
| Purchase commitments ($m) | n/a | 1,101.1 |
| Effective tax rate (%) | 25.2 | 25.4 |
| Diluted shares (m) | 128.5 | 117.6 |
| Company and measure | Period | Filed detail | Sales ($m) | Growth (%) | Gross margin (%) |
|---|---|---|---|---|---|
| BellRing RTD shakes and other beverages | Sep 2026 quarter (Q4 FY2026) | Premier RTD volume +16.5%, price/mix (8.6%) | 568.8 | +7.7% | 22.0 |
| BellRing RTD shakes and other beverages | FY2026 (Sep 2026) | Premier RTD volume +8.4%, price/mix (5.8%) | 1,943.2 | +2.6% | 26.6 |
| Simply Good Foods, total | Aug 2026 quarter (Q4 FY2026) | OWYN (20.6%), Atkins (14.9%) | 333.3 | (9.7%) | 34.0 |
| Abbott adult nutrition | Q3 2026 | US adult $381m, +3.5% | 1,199.0 | +2.0% | n/a |
| Celsius Alani Nu | Q3 2026 | company gross margin shown | 410.1 | +23.5% | 46.8 |
| Post Foodservice | Jun 2026 quarter (Q3 FY2026) | volume +4.3%, incl. higher protein shake production | 652.9 | (6.5%) | n/a |
| Post Weetabix | Jun 2026 quarter (Q3 FY2026) | volume (3.8%) | 137.1 | (0.6%) | n/a |
| Company and measure | Period | Filed detail | Sales ($m) | Growth (%) | Gross margin (%) |
|---|---|---|---|---|---|
| BellRing powders | Sep 2026 quarter (Q4 FY2026) | Premier powder consumption (1.8%) | 108.2 | +3.1% | n/a |
| BellRing Dymatize | FY2026 (Sep 2026) | price/mix +9.1%, volume +1.6% | 309.8 | +10.7% | n/a |
| Simply Good Foods, total | FY2026 (Aug 2026) | Quest +0.7%, Atkins (20.9%) | 1,356.5 | (6.5%) | 32.6 |
| Abbott nutrition, total | Q3 2026 | pediatric +8.8%, adult +2.0% | 2,262.0 | +5.1% | n/a |
| Celsius Holdings, total | Q3 2026 | international +78% | 847.2 | +16.8% | 46.8 |
| Company | Period | Gross margin | Change | Filed detail |
|---|---|---|---|---|
| BellRing | FY2026 (Sep 2026) | 26.6% against 33.3% | (6.7 pts) | Adjusted EBITDA margin 12.0% against 20.8% |
| BellRing | Sep 2026 quarter (Q4 FY2026) | 22.0% against 28.9% | (6.9 pts) | about $16m of inventory related actions |
| Simply Good Foods | FY2026 (Aug 2026) | 32.6% against 36.2% | (3.6 pts) | FY2027 gross margin guided +250 to 300 basis points |
| Celsius Holdings | Q3 2026 | 46.8% against 51.3% | (4.5 pts) | aluminum and fuel inflation, DSD mix |
| Post Holdings | Jun 2026 quarter (Q3 FY2026) | 29.1% against 30.0% | (0.9 pts) | avian influenza pricing lapped |
| Line item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | 1,371.5 | 1,666.8 | 1,996.2 | 2,316.6 | 2,398.4 |
| Gross profit | 421.8 | 530.2 | 707.3 | 770.4 | 638.1 |
| Selling, general and administrative | 189.7 | 216.3 | 284.6 | 396.0 | 343.4 |
| Operating income | 212.4 | 287.3 | 387.7 | 357.4 | 277.7 |
| Net income | 82.3 | 165.5 | 246.5 | 216.2 | 147.4 |
| Diluted EPS ($) | 0.88 | 1.23 | 1.86 | 1.68 | 1.25 |
| Operating cash flow | 21.0 | 215.6 | 199.6 | 260.6 | 126.0 |
| Capital expenditure | (1.8) | (1.8) | (1.8) | (4.7) | (9.4) |
| Free cash flow | 19.2 | 213.8 | 197.8 | 255.9 | 116.6 |
| Stock based compensation | 9.8 | 14.2 | 21.0 | 22.1 | 23.5 |
| Cash and investments | 35.8 | 48.4 | 70.8 | 71.8 | 20.1 |
| Total debt | 929.5 | 856.8 | 833.1 | 1,084.3 | 1,045.6 |
| Total equity | (376.2) | (323.5) | (205.9) | (453.9) | (425.5) |
| Metric | Q4 FY2025 | Q4 FY2026 | Change |
|---|---|---|---|
| Revenue ($m) | 648.2 | 692.0 | 6.8% |
| Gross profit ($m) | 187.4 | 152.3 | (18.7%) |
| Operating income ($m) | 102.2 | 67.8 | (33.7%) |
| Net income ($m) | 59.6 | 35.6 | (40.3%) |
| Diluted EPS ($) | 0.48 | 0.31 | (35.4%) |
| Operating cash flow ($m) | 169.1 | 61.0 | (63.9%) |
| Free cash flow ($m) | 168.1 | 59.7 | (64.5%) |
| Operating margin (%) | 15.8 | 9.8 | (6.0 pts) |
| Net margin (%) | 9.2 | 5.1 | (4.1 pts) |
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Growth and margins | |||||
| Revenue growth (%) | n/a | 21.5 | 19.8 | 16.1 | 3.5 |
| Gross margin (%) | 30.8 | 31.8 | 35.4 | 33.3 | 26.6 |
| Operating margin (%) | 15.5 | 17.2 | 19.4 | 15.4 | 11.6 |
| Net margin (%) | 6.0 | 9.9 | 12.3 | 9.3 | 6.1 |
| FCF margin (%) | 1.4 | 12.8 | 9.9 | 11.0 | 4.9 |
| Cost and investment intensity | |||||
| SBC (%) revenue | 0.7 | 0.9 | 1.1 | 1.0 | 1.0 |
| Capex (%) revenue | 0.1 | 0.1 | 0.1 | 0.2 | 0.4 |
| Effective tax rate (%) | 20.3 | 24.9 | 25.2 | 25.2 | 25.4 |
| Returns | |||||
| ROA (%) | 11.6 | 23.7 | 32.3 | 24.3 | 16.5 |
| ROIC (%) | 32.7 | 44.5 | 52.1 | 47.9 | 34.5 |
| Asset turnover (x) | 1.94 | 2.41 | 2.38 | 2.46 | 2.83 |
| Liquidity and leverage | |||||
| Current ratio (x) | 2.94 | 2.82 | 2.91 | 2.35 | 3.20 |
| Net cash ($bn) | (0.9) | (0.8) | (0.8) | (1.0) | (1.0) |
| Efficiency and cash quality | |||||
| Days sales outstanding | 46 | 37 | 40 | 35 | 33 |
| Inventory days | 77 | 62 | 81 | 78 | 67 |
| FCF to net income (x) | 0.23 | 1.29 | 0.80 | 1.18 | 0.79 |
| Shareholder returns (%) FCF | 223 | 59 | 74 | 186 | 118 |
| Measure | Value |
|---|---|
| Market cap ($bn) | 1.6 |
| Enterprise value ($bn) | 2.6 |
| P/E (TTM) (x) | 10.9 |
| EV/Sales (TTM) (x) | 1.1 |
| EV/EBITDA (TTM) (x) | 9.1 |
| FCF yield (%) | 7.3 |
| Line | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Q4 FY2026 |
|---|---|---|---|---|---|
| Cost of goods sold (% of net sales) | 71.1 | 70.1 | 73.0 | 71.4 | 78.0 |
| Gross profit (% of net sales) | 28.9 | 29.9 | 27.0 | 28.6 | 22.0 |
| Selling, general and administrative (% of net sales) | 12.5 | 14.5 | 15.3 | 16.4 | 11.6 |
| Operating profit (% of net sales) | 15.8 | 14.6 | 11.0 | 11.5 | 9.8 |
| Net earnings (% of net sales) | 9.2 | 8.1 | 5.7 | 6.0 | 5.1 |
| Adjusted EBITDA (company measure) (% of net sales) | 18.1 | 16.8 | 9.0 | 13.7 | 9.6 |
| Line | Q4 FY2025 | Q4 FY2026 | Change |
|---|---|---|---|
| Net sales | 648.2 | 692.0 | 43.8 |
| Cost of goods sold | (460.8) | (539.7) | (78.9) |
| Gross profit | 187.4 | 152.3 | (35.1) |
| Selling, general and administrative | (80.9) | (80.2) | 0.7 |
| Amortization of intangible assets | (4.3) | (4.3) | 0.0 |
| Operating profit | 102.2 | 67.8 | (34.4) |
| Interest expense, net | (19.1) | (20.0) | (0.9) |
| Income tax | (23.5) | (12.2) | 11.3 |
| Net earnings | 59.6 | 35.6 | (24.0) |
| Adjusted EBITDA (company measure) | 117.4 | 66.4 | (51.0) |
| Item | Outlook | Source |
|---|---|---|
| FY2027 net sales | $2.32bn to $2.42bn | 8-K Ex 99.1, 18 Nov 2026 |
| FY2027 Adjusted EBITDA | $310m to $350m | same |
| FY2027 Adjusted EBITDA % of net sales | about 14% | same |
| FY2027 capital expenditure | $3m | same |
| Long term targets | net sales growth 7% to 9% and Adjusted EBITDA margin 18% to 20% (Nov 2025) withdrawn; update due with Q2 FY2027 results | same |
| Supply chain savings program | at least $100m gross over three fiscal years; about $25m in FY2027 | 10-K FY2026 Item 7 |
| Speaker | Date and source | Statement |
|---|---|---|
| Michael Axelrod, President and CEO | 18 Nov 2026, 8-K Ex 99.1 | “Fiscal 2027 will be a year of strengthening our foundation” |
| Item | Disclosure |
|---|---|
| Item 7, cost program | Supply chain optimization targeting at least $100m of gross savings over three fiscal years from co manufacturing, procurement, distribution and packaging; about $25m in FY2027. |
| Item 7, operating profit | Operating profit (22%): net product costs +$135.8m, advertising +$16.0m, reorganization $5.9m, against the $69.0m legal provision of FY2025; commodity derivatives a $62.7m favorable change. |
| Item 7, inventory | Inventory adjustments of $18.1m of excess inventory reserves and an $11.3m charge for a supplier ingredient that missed quality requirements. |
| Item 7, tariffs | Tariffs, geopolitical conflicts and trade policies raised raw material, packaging, manufacturing and freight costs, with a material adverse effect on results. |
| Item 7, liquidity | Revolver borrowings $420.0m and repayments $460.0m in FY2026; $287.6m available at 30 Sep 2026; weighted average interest rate 6.7% against 7.1%. |
| Item 7, commitments | Purchase commitments $1.10bn, of which $559.3m due in FY2027, extending to FY2033. |
| Item 5, repurchases | $506.9m left under the $600m authorization that expires 19 Nov 2027; no repurchases in Q4 FY2026. |
| Note 14, litigation | Securities class action filed 22 Jan 2026; on 28 Jul 2026 the court dismissed claims for 6 Aug 2024 to 5 May 2025 and kept claims for 6 May 2025 to 4 May 2026; class certification hearing 3 Dec 2026; derivative suits in Delaware. |
| Note 14, Joint Juice | $90.0m paid into settlement funds in FY2026; all Joint Juice liabilities settled at 30 Sep 2026. |
| Measure | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Q4 FY2026 | FY2026 |
|---|---|---|---|---|---|---|
| Total net sales, growth | +16.6% | +0.8% | +1.8% | +4.2% | +6.8% | +3.5% |
| Total net sales, volume | +19.2% | +0.7% | +10.8% | +1.7% | +14.9% | +7.6% |
| Total net sales, price/mix | (2.6%) | +0.1% | (9.0%) | +2.5% | (8.1%) | (4.1%) |
| Premier Protein, growth | +14.9% | (1.2%) | +1.7% | +0.7% | +7.1% | +2.3% |
| Premier Protein, volume | +18.4% | (0.2%) | +11.3% | +1.5% | +16.0% | +7.8% |
| Premier Protein, price/mix | (3.5%) | (1.0%) | (9.6%) | (0.8%) | (8.9%) | (5.5%) |
| Premier Protein RTD, growth | +14.1% | (2.2%) | +2.3% | +1.2% | +7.9% | +2.6% |
| Premier Protein RTD, volume | +18.4% | (0.3%) | +11.7% | +3.1% | +16.5% | +8.4% |
| Premier Protein RTD, price/mix | (4.3%) | (1.9%) | (9.4%) | (1.9%) | (8.6%) | (5.8%) |
| Dymatize, growth | +32.9% | +15.8% | (1.9%) | +26.7% | +3.6% | +10.7% |
| Dymatize, volume | n/a | n/a | (6.8%) | +6.0% | (14.6%) | +1.6% |
| Dymatize, price/mix | n/a | n/a | +4.9% | +20.7% | +18.2% | +9.1% |
| Premier RTD consumption | +20.4% | (2.2%) | +2.9% | +6.0% | +8.8% | n/a |
| Premier powder consumption | +16.9% | +2.9% | +3.1% | (4.2%) | (1.8%) | n/a |
| Dymatize consumption | (1.5%) | +7.5% | +6.0% | +2.7% | +12.1% | n/a |
| Measure | 18 Nov 2025 | 3 Feb 2026 | 5 May 2026 | 4 Aug 2026 | FY2026 actual |
|---|---|---|---|---|---|
| Net sales | $2.41bn to $2.49bn | $2.41bn to $2.46bn | $2.325bn to $2.365bn | $2.335bn to $2.375bn | $2.40bn |
| Adjusted EBITDA | $425m to $455m | $425m to $440m | $315m to $335m | $275m to $295m | $288.8m |
| Long term targets | sales +7% to 9%; margin 18% to 20% | unchanged | unchanged | unchanged | withdrawn 18 Nov 2026 |
| Company | Revenue TTM ($bn) | Revenue growth (%) | Gross margin (%) | Operating margin (%) | Net margin (%) | FCF margin (%) | ROE (%) | Net cash ($bn) | Market value ($bn) | EV/Sales (x) | P/E TTM (x) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BRBR | 2.4 | 6.8 | 26.6 | 11.6 | 6.1 | 4.9 | n/a | (1.0) | 2 | 1.1 | 10.9 |
| SMPL | 1.4 | (9.7) | 32.6 | (13.2) | (11.5) | 11.6 | (9.6) | (0.2) | 1 | 1.0 | n/a |
| CELH | 3.2 | 16.8 | 47.6 | 13.0 | 7.3 | 8.5 | 18.6 | 0.0 | 8 | 2.6 | 36.8 |
| POST | 8.4 | (1.8) | 28.8 | 9.6 | 3.5 | 6.6 | 8.3 | (7.4) | 4 | 1.3 | 14.7 |
| Date | Items | Event |
|---|---|---|
| 20 Nov 2025 | 8.01, 9.01 | New $600m share repurchase authorization to 19 Nov 2027; the prior $400m authorization (about $123m used) was cancelled (Ex 99.1). (0001628280-25-053329) |
| 2 Feb 2026 | 5.07 | Annual meeting of 28 Jan 2026: five directors elected (Robert Vitale 73.9% of votes cast); PwC ratified with 99.98% of votes cast; say on pay 82.6% of votes cast. (0001628280-26-004642) |
| 3 Feb 2026 | 2.02, 5.02, 9.01 | Q1 FY2026 results: net sales $537.3m, +0.8%; Adjusted EBITDA $90.3m; FY2026 outlook narrowed to $2.41bn to $2.46bn and $425m to $440m (Ex 99.1, 99.2). CEO Darcy Davenport to retire (Ex 99.3). (0001628280-26-004789) |
| 23 Feb 2026 | 5.02 | Retention RSU grants to four executives during the CEO transition, $451k to $551k each, vesting after one year. (0001628280-26-010629) |
| 5 May 2026 | 2.02, 9.01 | Q2 FY2026 results: net sales $598.7m, +1.8% (volume +10.8%, price/mix (9.0%)); $11.3m ingredient charge; FY2026 outlook cut to $2.325bn to $2.365bn and Adjusted EBITDA $315m to $335m (Ex 99.1, 99.2). (0001628280-26-030115) |
| 24 Jun 2026 | 5.02, 8.01 | Workforce realignment: about $6m of one time charges, $10m to $12m of annual savings; Chief Growth Officer Douglas Cornille leaves 1 Sep 2026. (0001628280-26-045287) |
| 8 Jul 2026 | 5.02, 7.01, 9.01 | Michael Axelrod appointed President and CEO from 29 Jul 2026: salary $1.0m, equity award $4.75m (Ex 99.1). (0001628280-26-047674) |
| 4 Aug 2026 | 2.02, 9.01 | Q3 FY2026 results: net sales $570.4m, +4.2%; $10.0m excess bottle inventory charge; FY2026 Adjusted EBITDA outlook cut to $275m to $295m (Ex 99.1, 99.2). (0001628280-26-052137) |
| 18 Nov 2026 | 2.02, 5.02, 7.01, 9.01 | Q4 FY2026 results: net sales $692.0m, +6.8%; FY2026 $2.40bn, +3.5%; FY2027 outlook net sales $2.32bn to $2.42bn, Adjusted EBITDA $310m to $350m; long term targets withdrawn (Ex 99.1, 99.2). CFO Paul Rode succeeded by Travis Leonard from 1 Dec 2026 (Ex 99.3). (0001628280-26-074645) |
| Contract | Terms |
|---|---|
| 7.00% senior notes | $840.0m due Mar 2030; indenture limits debt, liens, dividends and repurchases, with suspension if rated investment grade. |
| Credit agreement, first amendment (Aug 2025) | $500m revolver to 22 Aug 2030 (14 Dec 2029 if the notes are not refinanced); $210.0m drawn at 30 Sep 2026; 6.16% rate. |
| Contract manufacturing agreement | Largest RTD contract manufacturer, 42.3% of Premier RTD supply in FY2026, minimum quarterly volumes, expires 31 Dec 2030 (10-K). |
| Protein powder supply agreement | Minimum periodic purchase volumes with the largest protein powder supplier, expires 30 Jun 2028 (10-K). |
| Share repurchase authorization | $600m from 19 Nov 2025 to 19 Nov 2027; $506.9m left at 30 Sep 2026. |
| CEO and CFO agreements | CEO: salary $1.0m, $4.75m equity award, severance 2.0x (3.0x on change in control), transaction bonus of one year salary; CFO: salary $580k, $985k equity award, severance 1.0x (2.0x). |
| Proposal | For (m votes) | Against (m votes) | Abstain (m votes) | For as % of votes cast | Result |
|---|---|---|---|---|---|
| Elect Robert V. Vitale | 69.5 | 24.6 | 0.0 | 73.9 | Elected |
| Elect Darcy H. Davenport | 92.5 | 1.6 | 0.0 | 98.3 | Elected |
| Elect David I. Finkelstein | 93.0 | 1.2 | 0.0 | 98.8 | Elected |
| Elect Chonda J. Nwamu | 92.5 | 1.6 | 0.0 | 98.3 | Elected |
| Elect Elliot H. Stein, Jr. | 89.1 | 5.0 | 0.0 | 94.7 | Elected |
| Ratify PricewaterhouseCoopers for FY2026 | 100.1 | 0.0 | 0.3 | 100.0 | Approved |
| Say on pay (advisory) | 77.5 | 16.3 | 0.3 | 82.6 | Approved |
| Holder | Shares (m) | Share of class (%) | Basis |
|---|---|---|---|
| BlackRock, Inc. | 9.00 | 7.7 | 13G/A 27 Oct 2026, at 30 Sep 2026 |
| The Goldman Sachs Group, Inc. | 7.77 | 6.7 | 13G 9 Nov 2026, at 30 Sep 2026 |
| Vanguard Capital Management | 6.11 | 5.2 | 13G 3 Sep 2026, at 31 Mar 2026 |
| Vanguard Portfolio Management | 6.00 | 5.11 | 13G 3 Sep 2026, at 31 Mar 2026 |
| Insider | Type | Shares | Price ($) |
|---|---|---|---|
| David Finkelstein, director (29 Jan 2026) | Purchase | 2,000 | 17.75 |
| David Finkelstein, director (13 May 2026) | Purchase | 4,000 | 9.24 |
| Shawn Conway, director (8 Sep 2026) | Purchase | 2,022 | 9.89 |
| Douglas Cornille, Chief Growth Officer, Rule 10b5‑1 sale (1 Dec 2025) | Sale | 3,970 | 30.93 |
| Risk | Disclosure and change |
|---|---|
| Dependence on Premier Protein RTD shakes | RTD Beverages 81.0% of FY2026 net sales; Q4 price/mix (8.6%) on Premier RTD as promotions rose. |
| Customer concentration | Walmart, Costco and Amazon 73.6% of FY2026 net sales; no material long term supply agreements with customers. |
| Contract manufacturers and suppliers | One manufacturer supplied 42.3% of Premier RTD shakes; sole supplier for aseptic packaging; purchase commitments $1.10bn. |
| Protein and input costs, tariffs | Net product costs +$135.8m in FY2026; gross margin 26.6% against 33.3%; hedges change fair value by about $14m per 10% price move. |
| Debt | Debt principal $1.05bn against FY2026 Adjusted EBITDA $288.8m; 7.00% notes due Mar 2030 and revolver to Aug 2030. |
| Securities litigation | Class action for 6 May 2025 to 4 May 2026 continues; class certification hearing 3 Dec 2026; derivative suits pending. |
| Leadership change | New CEO from 29 Jul 2026 and new CFO from 1 Dec 2026; long term targets withdrawn pending a strategy review. |
| Measure | 10-K FY2025 | 10-K FY2026 |
|---|---|---|
| Risk factors (count) | 48 | 48 |
| Words in Item 1A | 16,036 | 15,851 |
| Change | Risk factor | What changed |
|---|---|---|
| Added | Modernizing and adopting new technologies incl. AI | New factor: competitors may adopt AI and new technologies faster; misuse or inaccurate AI outputs may harm reputation. |
| Added | Securities litigation and stockholder activism | New factor: BellRing and current and former officers and directors are defendants in a securities class action and derivative suits filed in 2026. |
| Removed | Tax liabilities relating to the spin off | Removed. |
| Removed | spin off failing to qualify as tax free | Removed. |
| Reworded | Dependence on RTD shakes and other beverages | Heading widened from RTD protein shakes to RTD shakes and other beverages; RTD Beverages 81.0% of FY2026 net sales. |
| Reworded | Labor related costs | Adds wage inflation, competition for talent and healthcare cost inflation; about 480 employees at 1 Nov 2026. |
| Reworded | Changes in tax laws | Adds federal, state, local and foreign tax law changes and audits by taxing authorities. |
| Reworded | Interest rates | Adds that rising rates may limit new borrowing or refinancing on acceptable terms. |
| Reworded | Standalone corporate infrastructure costs | Updated for the expiry of the master services agreement with Post. |
| Factor | Current value | Best case requires | Evidence in filings |
|---|---|---|---|
| Premier RTD price/mix | (8.6%) in Q4 FY2026 | promotional spend stabilizes and price/mix turns flat | 8-K Ex 99.1; 25% of RTD category volume on price reduction (Ex 99.2) |
| Premier RTD volume and distribution | volume +16.5%, distribution points +36% in Q4 | distribution gains hold with lower promotion | 8-K Ex 99.2 |
| Protein and input costs | gross margin 26.6% FY2026 | cost inflation and tariffs ease; gross margin back near 30% | 10-K Item 7: net product costs +$135.8m |
| Supply chain savings | program announced Nov 2026 | $100m gross savings delivered over three years | 10-K Item 7; about $25m in FY2027 |
| Club channel | Premier RTD club consumption (6.4%) over 52 weeks | club returns to growth | 8-K Ex 99.2 |
| Leverage | 3.6x net debt to Adjusted EBITDA | debt paid down from free cash flow before the 2030 maturities | 10-K Note 13 |
| Measure | Worst case | Base case | Best case |
|---|---|---|---|
| Revenue CAGR, 3 years (%) | (3.0) | 1.0 | 4.0 |
| Revenue, FY2029 ($bn) | 2.2 | 2.5 | 2.7 |
| Operating margin, FY2029 (%) | 8.0 | 12.0 | 15.0 |
| Net income, FY2029 ($bn) | 0.1 | 0.2 | 0.2 |
| EPS, FY2029 ($) | 0.61 | 1.42 | 2.20 |
| Exit P/E (x) | 9.0 | 12.0 | 16.0 |
| Implied price ($) | 5.52 | 17.09 | 35.24 |
| Change against $13.66 (%) | (60) | 25 | 158 |
| Implied annual return (%) | (26.1) | 7.7 | 37.1 |
| Description | Share loss and persistent cost inflation | Net sales near the FY2027 outlook (report assumption) | Promotions ease and savings arrive |
| Revenue CAGR \ Operating margin | 8% | 10% | 12% | 14% | 16% |
|---|---|---|---|---|---|
| (3%) | $7.51 | $10.96 | $14.41 | $17.87 | $21.32 |
| (1%) | $8.38 | $12.05 | $15.72 | $19.40 | $23.07 |
| 1% | $9.29 | $13.19 | $17.09 | $20.99 | $24.88 |
| 3% | $10.23 | $14.37 | $18.50 | $22.64 | $26.77 |
| 5% | $11.21 | $15.60 | $19.98 | $24.36 | $28.74 |
| Exit P/E \ Operating margin | 8% | 10% | 12% | 14% | 16% |
|---|---|---|---|---|---|
| 8x | $6.19 | $8.79 | $11.39 | $13.99 | $16.59 |
| 10x | $7.74 | $10.99 | $14.24 | $17.49 | $20.74 |
| 12x | $9.29 | $13.19 | $17.09 | $20.99 | $24.88 |
| 14x | $10.83 | $15.38 | $19.93 | $24.48 | $29.03 |
| 16x | $12.38 | $17.58 | $22.78 | $27.98 | $33.18 |
This analysis is for information only and is not financial advice. It is derived from public SEC filings retrieved via sec-api.io and is not a publication of the U.S. Securities and Exchange Commission. Scenario values are model outputs under stated assumptions and are not forecasts. Data as of 19 November 2026.
All company and peer figures are read from SEC filings retrieved through the sec-api.io MCP server. Category data are those BellRing reports in its 8-K Ex 99.2. Share prices are regular session closes as dated in the text.
| Form | Period | Filed | Accession number |
|---|---|---|---|
| 8-K Ex 99.1, 99.2, 99.3 | 30 Sep 2026 | 18 Nov 2026 | 0001628280-26-074645 |
| 10-K | 30 Sep 2026 | 18 Nov 2026 | 0001772016-26-000027 |
| 10-Q | 30 Jun 2026 | 4 Aug 2026 | 0001772016-26-000022 |
| 10-Q | 31 Mar 2026 | 5 May 2026 | 0001772016-26-000012 |
| 10-Q | 31 Dec 2025 | 3 Feb 2026 | 0001772016-26-000007 |
| 10-K | 30 Sep 2025 | 18 Nov 2025 | 0001772016-25-000153 |
| 10-K | 30 Sep 2024 | 19 Nov 2024 | 0001772016-24-000108 |
| 10-K | 30 Sep 2023 | 21 Nov 2023 | 0001772016-23-000091 |
| 10-Q | 30 Jun 2025 | 5 Aug 2025 | 0001772016-25-000127 |
| 10-Q | 31 Mar 2025 | 6 May 2025 | 0001772016-25-000081 |
| 10-Q | 31 Dec 2024 | 4 Feb 2025 | 0001772016-25-000028 |
| 8-K Ex 99.1 | 30 Sep 2025 | 18 Nov 2025 | 0001628280-25-052773 |
| 8-K Items 8.01, 9.01 | 20 Nov 2025 | 20 Nov 2025 | 0001628280-25-053329 |
| 8-K Items 5.07 | 2 Feb 2026 | 2 Feb 2026 | 0001628280-26-004642 |
| 8-K Items 2.02, 5.02, 9.01 | 3 Feb 2026 | 3 Feb 2026 | 0001628280-26-004789 |
| 8-K Items 5.02 | 23 Feb 2026 | 23 Feb 2026 | 0001628280-26-010629 |
| 8-K Items 2.02, 9.01 | 5 May 2026 | 5 May 2026 | 0001628280-26-030115 |
| 8-K Items 5.02, 8.01 | 24 Jun 2026 | 24 Jun 2026 | 0001628280-26-045287 |
| 8-K Items 5.02, 7.01, 9.01 | 8 Jul 2026 | 8 Jul 2026 | 0001628280-26-047674 |
| 8-K Items 2.02, 9.01 | 4 Aug 2026 | 4 Aug 2026 | 0001628280-26-052137 |
| Schedule 13G/A, BlackRock | 30 Sep 2026 | 27 Oct 2026 | 0002012383-26-003760 |
| Schedule 13G, Goldman Sachs | 30 Sep 2026 | 9 Nov 2026 | 0000886982-26-000538 |
| Schedule 13G, Vanguard Capital Management | 31 Mar 2026 | 3 Sep 2026 | 0002100119-26-001529 |
| Schedule 13G, Vanguard Portfolio Management | 31 Mar 2026 | 3 Sep 2026 | 0002100121-26-001019 |
| Schedule 13G/A, AQR | 30 Sep 2026 | 12 Nov 2026 | 0001167557-26-000230 |
| Schedule 13G/A, Ameriprise | 30 Sep 2026 | 16 Nov 2026 | 0001193125-26-462560 |
| Form 4, director purchase | 13 May 2026 | 14 May 2026 | 0001628280-26-035151 |
| Form 4, director purchase | 8 Sep 2026 | 9 Sep 2026 | 0001628280-26-061167 |
| Form 4, director purchase | 29 Jan 2026 | 11 Mar 2026 | 0001628280-26-016917 |
| Form 4, plan sale | 1 Dec 2025 | 3 Dec 2025 | 0001628280-25-055090 |
| Company | Form | Filed | Accession number |
|---|---|---|---|
| Abbott | 8-K Ex 99.1 | 21 Oct 2026 | 0001628280-26-066601 |
| Celsius Holdings | 10-K | 2 Mar 2026 | 0001341766-26-000024 |
| Celsius Holdings | 8-K Ex 99.1 | 5 Nov 2026 | 0001341766-26-000059 |
| Celsius Holdings | 10-Q | 5 Nov 2026 | 0001341766-26-000062 |
| Coca‑Cola | 8-K Item 8.01 | 16 Jul 2026 | 0001628280-26-048466 |
| Coca‑Cola | 8-K Ex 99.1 | 27 Oct 2026 | 0001628280-26-067403 |
| Post Holdings | 10-K | 21 Nov 2025 | 0001530950-25-000260 |
| Post Holdings | 8-K Ex 99.1 | 6 Aug 2026 | 0001530950-26-000076 |
| Post Holdings | 10-Q | 6 Aug 2026 | 0001530950-26-000077 |
| Simply Good Foods | 8-K Ex 99.1 | 27 Oct 2026 | 0001702744-26-000028 |
| Simply Good Foods | 10-K | 27 Oct 2026 | 0001702744-26-000031 |
| Filed | Exhibit | Document | Content |
|---|---|---|---|
| 20 Nov 2025 | Ex 99.1 | $600m repurchase authorization | $600m authorization over two years from 19 Nov 2025; about $123m bought under the cancelled $400m authorization of 2 Sep 2025 |
| 3 Feb 2026 | Ex 99.1 | Q1 FY2026 results | net sales $537.3m, +0.8%; gross margin 29.9% against 37.5%; 3.0m shares bought for $96.9m at $31.95; $543.1m authorization left |
| 3 Feb 2026 | Ex 99.2 | Q1 FY2026 supplemental presentation | Premier RTD consumption (2.2%), Premier powder +2.9%, Dymatize +7.5% (13 weeks); consumption data are third party market data and management estimates of untracked channels as filed |
| 3 Feb 2026 | Ex 99.3 | CEO leadership transition | CEO Darcy Davenport to retire on the earlier of a successor appointment or 30 Sep 2026; external search for a successor |
| 5 May 2026 | Ex 99.1 | Q2 FY2026 results | net sales $598.7m, +1.8%: volume +10.8%, price/mix (9.0%); $11.3m charge for an ingredient that failed quality standards; FY2026 Adjusted EBITDA outlook $315m to $335m |
| 5 May 2026 | Ex 99.2 | Q2 FY2026 supplemental presentation | Premier RTD consumption +2.9%, powder +3.1%, Dymatize +6.0% (13 weeks) |
| 8 Jul 2026 | Ex 99.1 | CEO appointment | Michael Axelrod, former CEO of Snak King and Del Real Foods, CEO from 29 Jul 2026; base salary $1.0m; equity award $4.75m, 40% RSUs and 60% PRSUs |
| 4 Aug 2026 | Ex 99.1 | Q3 FY2026 results | net sales $570.4m, +4.2%; Dymatize +26.7% on price/mix +20.7%; $10.0m excess shake bottle inventory charge; FY2026 Adjusted EBITDA outlook $275m to $295m |
| 4 Aug 2026 | Ex 99.2 | Q3 FY2026 supplemental presentation | Premier RTD consumption +6.0%, powder (4.2%), Dymatize +2.7% (13 weeks) |
| 18 Nov 2026 | Ex 99.1 | Q4 and FY2026 results, FY2027 outlook | Q4 net sales $692.0m, +6.8%: volume +14.9%, price/mix (8.1%); Adjusted EBITDA $66.4m; FY2027 net sales $2.32bn to $2.42bn, Adjusted EBITDA $310m to $350m; long term targets withdrawn |
| 18 Nov 2026 | Ex 99.2 | Q4 FY2026 supplemental presentation | RTD category +12%, ready to mix +9% (13 weeks); 25% of RTD volume sold on price reduction; Premier RTD share 23.1%; distribution points +36%; household penetration 22.4%, repeat rate 54% |
| 18 Nov 2026 | Ex 99.3 | CFO transition | Travis Leonard, former CFO of Lockton and Hostess Brands, CFO from 1 Dec 2026; Paul Rode advises to 28 Feb 2027 |